Mitochondrial-targeted therapy for osteoarthritis: Challenges and opportunities from basic research to clinical...

Area of Science:

• Mitochondrial biology
• Degenerative joint diseases
• Pharmacological interventions

Background:

• Osteoarthritis (OA) is a major cause of disability, with current treatments offering only symptomatic relief.
• Mitochondrial dysfunction is a key factor in OA pathogenesis, involving oxidative stress, altered dynamics, and impaired metabolism.
• Existing OA therapies do not address the underlying disease mechanisms driven by mitochondria.

Purpose of the Study:

• To review mitochondrial-targeted therapeutic strategies for osteoarthritis.
• To highlight mechanisms of mitochondrial dysfunction in OA cartilage degeneration.
• To discuss challenges and future directions for clinical translation of these therapies.

Main Methods:

• Review of preclinical and clinical studies on mitochondrial dysfunction in OA.
• Analysis of therapeutic approaches targeting mitochondrial pathways.
• Identification of barriers to clinical translation of OA treatments.

Main Results:

• Mitochondrial dysfunction, including ROS production, altered dynamics, and metabolic shifts, accelerates OA.
• Mitochondrial-targeted strategies (antioxidants, dynamics regulators, autophagy activators, biogenesis enhancers, transplantation) show preclinical efficacy.
• Clinical translation of these OA therapies is limited by delivery issues, disease heterogeneity, and model constraints.

Conclusions:

• Mitochondrial-targeted therapies offer a promising avenue for halting OA progression.
• Overcoming challenges in drug delivery, patient stratification, and model development is crucial for clinical success.
• Future research should focus on developing advanced delivery systems and humanized models for OA treatment.